<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="233443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036231</url>
  </required_header>
  <id_info>
    <org_study_id>RG1068-03</org_study_id>
    <nct_id>NCT00036231</nct_id>
  </id_info>
  <brief_title>Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repligen Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repligen Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of multiple doses of secretin on autism.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <condition>Autism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RG1068 (Synthetic Human Secretin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Autism

          -  Gastrointestinal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>32 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.repligen.com</url>
  </link>
  <verification_date>August 2005</verification_date>
  <lastchanged_date>November 17, 2005</lastchanged_date>
  <firstreceived_date>May 8, 2002</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
